Rockwell Medical Inc (NASDAQ:RMTI) saw unusually large options trading on Thursday. Investors acquired 3,054 put options on the company. This represents an increase of approximately 3,815% compared to the typical daily volume of 78 put options.
A number of brokerages have recently weighed in on RMTI. BidaskClub lowered Rockwell Medical from a “hold” rating to a “sell” rating in a research note on Thursday. Zacks Investment Research lowered Rockwell Medical from a “hold” rating to a “sell” rating in a research note on Thursday, January 4th.
Rockwell Medical (NASDAQ RMTI) opened at $5.92 on Friday. Rockwell Medical has a 52 week low of $5.06 and a 52 week high of $8.98. The company has a market capitalization of $318.25, a price-to-earnings ratio of -13.77 and a beta of 2.02.
A number of institutional investors have recently bought and sold shares of the business. Bank of New York Mellon Corp increased its stake in Rockwell Medical by 6.5% during the 3rd quarter. Bank of New York Mellon Corp now owns 249,489 shares of the company’s stock worth $2,136,000 after acquiring an additional 15,271 shares during the period. Athos Capital Ltd bought a new position in Rockwell Medical during the 3rd quarter worth $6,834,000. Raymond James Financial Services Advisors Inc. bought a new position in Rockwell Medical during the 3rd quarter worth $107,000. National Asset Management Inc. bought a new position in Rockwell Medical during the 2nd quarter worth $203,000. Finally, State Street Corp increased its stake in Rockwell Medical by 7.4% during the 2nd quarter. State Street Corp now owns 903,142 shares of the company’s stock worth $7,160,000 after acquiring an additional 62,094 shares during the period. Hedge funds and other institutional investors own 21.26% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Rockwell Medical Sees Unusually High Options Volume (RMTI)” was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at https://www.americanbankingnews.com/2018/01/21/rockwell-medical-sees-unusually-high-options-volume-rmti.html.
About Rockwell Medical
Rockwell Medical, Inc (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process.
Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with MarketBeat.com's FREE daily email newsletter.